DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Protriptyline (Protriptyline Hydrochloride) - Summary

 
 



Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of protriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Protriptyline hydrochloride is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS : Information for Patients, and PRECAUTIONS: Pediatric Use.)

 

PROTRIPTYLINE SUMMARY

Protriptyline HCl is N -methyl-5H dibenzo[ a,d ]-cycloheptene-5-propanamine hydrochloride.

Protriptyline Hydrochloride Tablets, USP are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients.


See all Protriptyline indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Protriptyline

Modafinil found to improve memory in people recovering from depression
Source: Depression News From Medical News Today [2017.01.20]
A new study funded by the Medical Research Council (MRC) and Wellcome, and published in the journal Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, has found that the...

Clinical Depression: Osmosis Study Video
Source: Medscape Medical Students Headlines [2017.01.17]
This study video explores clinical depression, including postpartum, atypical, melancholic, and persistent depression.
Osmosis

TMS Approaches for Major Depression: Is There a Clear Winner?
Source: Medscape Psychiatry & Mental Health Headlines [2017.01.16]
Although no definitive recommendation can be made for particular types of stimulation, findings of a new review suggest that high-frequency stimulation is not the only technique superior to sham.
Medscape Medical News

OncoBreak: Cancer and Depression; Diagno$tic Te$t$; New Watson Study
Source: MedPage Today Gastroenterology [2017.01.12]
(MedPage Today) -- News, features, and commentary about cancer-related issues

New apps designed to reduce depression and anxiety as easily as checking your phone
Source: Anxiety / Stress News From Medical News Today [2017.01.09]
Soon you can seek mental health advice on your smartphone as quickly as finding a good restaurant.

more news >>

Published Studies Related to Protriptyline

Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. [1995.03]
A daily dose of 20 mg of protriptyline can improve daytime arterial blood gas tensions in chronic obstructive pulmonary disease (COPD)... Despite the low dose, anticholinergic side-effects occurred in most patients.

The use of protriptyline for respiratory failure in patients with chronic airflow limitation. [1990.07]
Treatment of nocturnal hypoventilation in patients with restrictive chest wall disease and respiratory failure, results in improved daytime arterial blood gas tensions, increase in functional ability and longer survival. Success has been achieved with the use of protriptyline which reduces the duration of rapid eye movement (REM) sleep during which nocturnal hypoventilation occurs.

Effect of protriptyline on ventilatory responses to hypercapnia and asphyxia in normal subjects. [1989.09]
A double-blind crossover study was undertaken to assess the effect of protriptyline on ventilatory responses in normal subjects. Seven subjects received in random order placebo, 10 mg and 20 mg protriptyline daily for 2 weeks... Mean HCVR and HVR following 10 mg and 20 mg protriptyline did not differ significantly from measurements on placebo, neither for the single dose study or after 2 weeks.

Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. [1988.10]
The role of drug therapy in the treatment of the sleep apnea/hypopnea syndrome is unclear. In a randomised, double-blind, placebo-controlled study, we investigated the value of 14-day therapy with protriptyline (20 mg daily) or acetazolamide (250 mg 4 times per day) on symptoms and on the frequency of apneas, hypopneas, arousals, and 4% desaturations in 10 patients with obstructive sleep apnea/hypopnea syndrome.

more studies >>

Clinical Trials Related to Protriptyline

Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions [Completed]
The objective of this study was to prove the bioequivalence of Protriptyline 10 mg tablets under fasted conditions

Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Completed]
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes of depression and may also reverse the reduction of volume caused by the depression. In addition, genetic markers for serotonin are implicated with depression, and may be an indication of reduced response to antidepressant treatments. This study aims to enroll patients who are defined as having treatment resistant depression (no remission after at least 2 treatments trials with an antidepressant). They will receive an MRI scan at the initial visit and either 6 months after sustained remission or 12 months after they enter the study for non-remitters. They will also be asked to give a blood sample for genotyping. They will be matched by age and handedness to healthy volunteers with no personal history of depression who will also receive an MRI scan and genotyping. The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It is anticipated that subjects will initially have smaller hippocampal volume but of those who sustain remission, there will be a small increase in hippocampal volume. It is also anticipated that specific genetic markers will be related to individuals response to antidepressant treatments.

more trials >>


Page last updated: 2017-01-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015